This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
|Articles|April 12, 2023
Meissner to Invest $250 Million in New Manufacturing Facility in US
Author(s)Alivia Leon
The new site will include state-of-the-art cleanroom facilities, laboratories, R&D, and office spaces.
Advertisement
Meissner, a company focused on advanced microfiltration and therapeutic manufacturing systems, announced on April 6, 2023 that it will invest nearly $250 million in a new manufacturing facility in Athens-Clarke County, Ga.
The new facility will be located at the Christian Industrial Tract in Winterville. When complete, the new campus will more than double the company’s manufacturing footprint in the United States as the company expands its current operations. The project is also expected to create more than 1700 new jobs over the next eight years, according to a company press release.
Operations are expected to begin in early 2026. The new site is expected to consist of multiple structures, which will include state-of-the-art cleanroom facilities, laboratories, R&D, and office spaces.
“We are thrilled to embark on this important expansion and are excited to build our second US manufacturing campus in Athens-Clarke County,” said Christopher Meissner, president of Meissner, in the press release. “The state of Georgia, and Athens-Clarke County in particular, is an ideal location with an incredible talent pool and strong geographic position that allows us to serve clients on the East Coast and throughout the world. We sincerely appreciate the partnership with state and county officials and are eager to break ground to join the community in Athens-Clarke County.”
Source: Meissner
Advertisement
Related to this article
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
4
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
5